Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pancreatic Neoplasms × acalabrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 22 Lymphoma, Mantle-Cell 15 Lymphoma, Large B-Cell, Diffuse 9 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Waldenstrom Macroglobulinemia 3 Leukemia, B-Cell 3 Leukemia 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuritis 1 Neoplasm, Residual 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Hematologic Neoplasms 1 Chromosome 17 deletion 1 Carcinoma, Non-Small-Cell Lung 1 Anemia, Hemolytic, Autoimmune 1

Interventions

Gemcitabine 268 Fluorouracil 72 Oxaliplatin 70 130-nm albumin-bound paclitaxel 59 Leucovorin 51 Capecitabine 48 Radiotherapy 47 Albumin-Bound Paclitaxel 47 Irinotecan 41 Cisplatin 34 Taxes 32 Erlotinib Hydrochloride 32 pembrolizumab 26 Radiosurgery 26 Docetaxel 25 S 1 (combination) 24 Bevacizumab 21 folfirinox 18 Nivolumab 17 Radiation 15 Magnetic Resonance Spectroscopy 15 Cyclophosphamide 15 Cetuximab 15 irinotecan sucrosofate 14 Drug Therapy 12 Surgical Procedures, Operative 11 Specimen Handling 10 Biopsy 10 Paclitaxel 9 Ipilimumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02362048 2019-10-01

KEYNOTE144

Acerta Pharma BV

Phase 2 Completed

77 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡